Mentor Capital Acquires 20% Stake Of Quantum Immunologics

Mentor Capital has acquired 20% stake in Quantum Immunologics, where Mentor Capital will provide equity funding to support Quantum Immunologics (QI) to complete the Phase I/II trials on metastatic breast cancer, which are now underway.

QI holds exclusive license to patents that pertain to certain therapeutic and diagnostic applications of the Oncofetal Antigen (OFA), a universal marker found on all tested cancer lines but not found in normal tissues.

In addition to providing $2.2 Million in funding to help support the FDA trials through approximately February 2010, Mentor Capital has agreed to assist QI in funding future strategic stock or cash acquisitions. Mentor will also stand by as a preferred funding source for QI during later stage or additional trials.

In exchange for thw financial support, Mentor Capital has received common stock in QI reflecting a carried interest of 20%. At the current private placement price for the QI shares, the acquisition of the QI position increases Mentor Capital assets per share by $3.74 per share.